Literature DB >> 21061097

The role of red yeast rice for the physician.

Ram Y Gordon1, David J Becker.   

Abstract

Red yeast rice is an ancient Chinese dietary staple and medication used by millions of patients as an alternative therapy for hypercholesterolemia. In recent years, the use of red yeast rice has grown exponentially due to increased public interest in complementary and alternative medications and the publication of several randomized, controlled trials demonstrating its efficacy and safety in different populations. The most promising role for red yeast rice is as an alternative lipid-lowering therapy for patients who refuse to take statins because of philosophical reasons or patients who are unable to tolerate statin therapy due to statin-associated myalgias. However, there is limited government oversight of red yeast rice products, wide variability of active ingredients in available formulations, and the potential of toxic byproducts. Therefore, until red yeast rice products are regulated and standardized, physicians and patients should be cautious in recommending this promising alternative therapy for hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21061097     DOI: 10.1007/s11883-010-0145-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  53 in total

1.  Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!

Authors:  Ram Y Gordon; Tod Cooperman; William Obermeyer; David J Becker
Journal:  Arch Intern Med       Date:  2010-10-25

2.  A 'natural' threat.

Authors:  Rodrigo Cartin-Ceba; Lee B Lu; Anna Kolpakchi
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

3.  Dietary supplement or drug? The case of cholestin.

Authors:  R J Havel
Journal:  Am J Clin Nutr       Date:  1999-02       Impact factor: 7.045

4.  An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.

Authors:  P N Durrington; D Bhatnagar; M I Mackness; J Morgan; K Julier; M A Khan; M France
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

Review 5.  Management of the patient with statin intolerance.

Authors:  Byron F Vandenberg; Jennifer Robinson
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

6.  Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

Authors:  Charles J Glueck; Dawit Aregawi; Mahlia Agloria; Qasim Khalil; Magdalena Winiarska; Jitender Munjal; Srikanth Gogineni; Ping Wang
Journal:  Clin Ther       Date:  2006-06       Impact factor: 3.393

7.  Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Authors:  Jian-Jun Li; Zong-Liang Lu; Wen-Rong Kou; Zuo Chen; Yang-Feng Wu; Xue-Hai Yu; Yu-Cheng Zhao
Journal:  J Clin Pharmacol       Date:  2009-08       Impact factor: 3.126

Review 8.  Nutritional supplements and serum lipids: does anything work?

Authors:  Mary P McGowan; Suzanne Proulx
Journal:  Curr Atheroscler Rep       Date:  2009-11       Impact factor: 5.113

9.  Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.

Authors:  Shannon M Rivers; Michael P Kane; Robert S Busch; Gary Bakst; Robert A Hamilton
Journal:  Endocr Pract       Date:  2007 Jan-Feb       Impact factor: 3.443

10.  Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

Authors:  Steven C Halbert; Benjamin French; Ram Y Gordon; John T Farrar; Kathryn Schmitz; Patti B Morris; Paul D Thompson; Daniel J Rader; David J Becker
Journal:  Am J Cardiol       Date:  2009-11-26       Impact factor: 2.778

View more
  10 in total

Review 1.  Red yeast rice for the treatment of dyslipidemia.

Authors:  Frances M Burke
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 2.  Red yeast rice for dysipidemia.

Authors:  Shariq Shamim; Firas J Al Badarin; James J DiNicolantonio; Carl J Lavie; James H O'Keefe
Journal:  Mo Med       Date:  2013 Jul-Aug

3.  Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system.

Authors:  Gabriela Mazzanti; Paola Angela Moro; Emanuel Raschi; Roberto Da Cas; Francesca Menniti-Ippolito
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

Review 4.  Evidence of lifestyle modification in the management of hypercholesterolemia.

Authors:  G S Mannu; M J S Zaman; A Gupta; H U Rehman; P K Myint
Journal:  Curr Cardiol Rev       Date:  2013-02-01

5.  Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia.

Authors:  Francesco Di Pierro; Pietro Putignano; Tarcisio Ferrara; Carmela Raiola; Giuliana Rapacioli; Nicola Villanova
Journal:  Clin Pharmacol       Date:  2016-12-21

6.  Perspectives on Functional Red Mold Rice: Functional Ingredients, Production, and Application.

Authors:  Feng Yanli; Yu Xiang
Journal:  Front Microbiol       Date:  2020-11-25       Impact factor: 5.640

7.  Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice.

Authors:  Jian Zou; Chunyan Yan; Jian-Bo Wan
Journal:  Chin Med       Date:  2022-01-25       Impact factor: 5.455

8.  Effect of Sodium Tanshinone IIA Sulfonate Injection on Blood Lipid in Patients With Coronary Heart Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Hufang Zhou; Ying Zhao; Wenhua Peng; Wenbo Han; Zichen Wang; Xiaoxia Ren; Dayang Wang; Guozhong Pan; Qian Lin; Xian Wang
Journal:  Front Cardiovasc Med       Date:  2021-11-24

9.  Complementary and alternative medicine and cardiovascular disease: an evidence-based review.

Authors:  Matthew J Rabito; Alan David Kaye
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-22       Impact factor: 2.629

10.  Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.

Authors:  Veronique Verhoeven; Maja Lopez Hartmann; Roy Remmen; Johan Wens; Sandra Apers; Paul Van Royen
Journal:  BMC Complement Altern Med       Date:  2013-07-18       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.